AUG 10 2004 j

SHEET 1 OF 1

Form PTO 1449		U.S. DEPARTMENT	OF COMMERCE	ATTY DOCKET NO. 245748USOCONT	1 2	SERIAL NO	D.				
(Modified)		PATENT AND TRAD	EMARK OFFICE	245748USOCONT BADE	y	10/716,80	65				
				APPLICANT							
LIST OF	REFEF	RENCES CITED BY API	PLICANT	Nobuya MATSUOKA, et al.							
				FILING DATE		GROUP					
				November 20, 2003		1623					
U.S. PATENT DOCUMENTS											
EXAMINER		DOCUMENT	DATE	NAME	CLASS	SUB	FILING DATE				
INITIAL		NUMBER				CLASS	IF APPROPRIATE				
	AA			<u> </u>							
	AB	 -									
	AC										
	AD										
	AE										
	AF										
	AG		<u></u>								
	AH				ļ						
	Al										
	AJ	· -									
	AK										
	AL				ļ		<u>.</u>				
	AM										
	AN										
			FO	REIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY		TRANSLATION YES NO					
72	AO	WO 00/24742	05/04/2000	WIPO							
	AP				_						
	AQ										
	AR										
	AS										
	AT										
	AU										
	AV										
		OTHER RE	FERENCES (Including Author, Title, Date, Pertinen	t Pages, e	tc.)					
Ol	AW	P. G. BARALDI, et al., Journal of Medicinal Chemistry, vol. 41, no. 12, XP-002163351, pages 2126-2133, "DESIGN, SYNTHESIS, AND BIOLOGICAL EVALUATION OF A SECOND GENERATION OF PYRAZOLO[4,3-e]-1,2,4-TRIAZOLO[1,5-c] PYRIMIDINES AS POTENT AND SELECTIVE A _{2A} ADENOSINE RECEPTOR ANTAGONISTS", 1999									
	AX										
	AY				,						
	AZ	Additional References sheet(s) attack					ences sheet(s) attached				
Examiner Date Considered //(o/											
*Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered Include copy of this form with next communication to applicant.											

105- 11/20/2003

..___ _ _

													
Form PTO 1449 U.S. DEPARTMENT OF COMMERCE (Modified) PATENT AND TRADEMARK OFFICE			ATTY DOCKET NO. 245748US0CONT	SERIAL NO. New Application									
LIST	OF REFEI	RENCES CITED BY APP	LICANT	APPLICANT Nobuya MATSUOKA, et al.									
				FILING DATE Herewith		GROUP 1614							
U.S. PATENT DOCUMENTS													
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE						
12	AA	4,925,849	05/15/90	Y. SHIOKAWA, et al.									
	AB	4,985,444	01/15/91	Y. SHIOKAWA, et al.									
	AC	5,204,346	04/20/93	Y. SHIOKAWA, et al.									
	AD	5,234,930	08/10/93	Y. SHIOKAWA, et al.									
	AE	5,773,530	06/30/98	A. AKAHANE, et al.									
(2)	AF	6,124,456	09/26/2000	A. AKAHANE, et al.									
- WO!	AG				1								
	AH												
	AI												
-	AJ												
	AK	<u></u>			1								
	AL												
<u> </u>	AM	·			 	 							
-					+	 	-						
	AN	J			<u> </u>	<u> </u>							
			FO	REIGN PATENT DOCUMENTS		,							
		DOCUMENT NUMBER	DATE	COUNTRY		YES	RANSLATION NO						
W/	AO	WO 98/03507	01/29/98	WIPO		<u> </u>							
	AP	590 919	04/06/93	EP		<u> </u>							
	AQ												
	AR												
	AS												
	AT				· ·								
	AU												
	AV												
		OTHER RE	FERENCES (Including Author, Title, Date, Pertine	nt Pages, e	etc.)							
							PTORS MODULATE						
ali	AW	HALOPERIDOL-INDUC	S. MANDHANE, et al., Eur. J. Pharmacol., Vol. 328, No. 2/3, pps. 135-141, "ADENOSINE A2 RECEPTORS MODULATE HALOPERIDOL-INDUCED CATALEPSY IN RATS", 1997										
	AX	J. MALLY, et al., Phamacol. Ther., Vol. 72, No. 3, pps. 243-250, "POTENTIAL ROLE OF ADENOSINE ANTAGONIST THERAPY IN PATHOLOGICAL TREMOR DISORDERS", 1996											
	AY	M. OHNO, et al., Neuroreport, Vol. 7, No. 18, pps. 3013-3016, "WORKING MEMORY FAILURE BY STIMULATION OF HIPPOCAMPAL ADENOSINE A1 RECEPTORS IN RATS", 1996											
	AZ	F. SUZUKI, et al., J. Med. Chem., Vol. 36, No. 17, pps. 2508-2518, "ADENOSINE A1 ANTAGONISTS. 3. STRUCTURE-ACTIVITY RELATIONSHIPS ON AMELIORATION AGAINST SCOPOLAMINE-OR N6- ((R) -PHENYLISOPROPYL) ADENOSINE-INDUCED COGNITIVE DISTURBANCE"											
Examiner		7.4.1			Date Co	nsidered	1/10/2000						
Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in													
leenformar	noo and n	at conditioned Include co	ov of this form	with next communication to applicant.									